HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
10
04
2024
accepted:
22
05
2024
medline:
19
7
2024
pubmed:
19
7
2024
entrez:
19
7
2024
Statut:
aheadofprint
Résumé
Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care. Overall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression. Individuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR. Between 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation is crucial to optimize HIV care.
METHODS
METHODS
Overall, 2386 HIV-1 protease/reverse transcriptase and 1831 integrase sequences from drug-naïve individuals diagnosed in north and central Italy between 2015 and 2021 were analysed. TDR was evaluated over time. Phylogeny was generated by maximum likelihood. Factors associated with TDR were evaluated by logistic regression.
RESULTS
RESULTS
Individuals were mainly male (79.1%) and Italian (56.2%), with a median (IQR) age of 38 (30-48). Non-B infected individuals accounted for 44.6% (N = 1065) of the overall population and increased over time (2015-2021, from 42.1% to 51.0%, P = 0.002). TDR prevalence to any class was 8.0% (B subtype 9.5% versus non-B subtypes 6.1%, P = 0.002) and remained almost constant over time. Overall, 300 transmission clusters (TCs) involving 1155 (48.4%) individuals were identified, with a similar proportion in B and non-infected individuals (49.7% versus 46.8%, P = 0.148). A similar prevalence of TDR among individuals in TCs and those out of TCs was found (8.2% versus 7.8%, P = 0.707).By multivariable analysis, subtypes A, F, and CFR02_AG were negatively associated with TDR. No other factors, including being part of TCs, were significantly associated with TDR.
CONCLUSIONS
CONCLUSIONS
Between 2015 and 2021, TDR prevalence in Italy was 8% and remained almost stable over time. Resistant strains were found circulating regardless of being in TCs, but less likely in non-B subtypes. These results highlight the importance of a continuous surveillance of newly diagnosed individuals for evidence of TDR to inform clinical practice.
Identifiants
pubmed: 39028674
pii: 7717140
doi: 10.1093/jac/dkae189
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Fondazione Aviralia
Investigateurs
F Ceccherini-Silberstein
(F)
M C Bellocchi
(MC)
L Carioti
(L)
M M Santoro
(MM)
M Andreoni
(M)
M Iannetta
(M)
A Bertoli
(A)
L Sarmati
(L)
V Malagnino
(V)
E Teti
(E)
D Armenia
(D)
A Antinori
(A)
F Baldini
(F)
R Bellagamba
(R)
G Berno
(G)
M Camici
(M)
S Cicalini
(S)
F De Zottis
(F)
R Esvan
(R)
L Fabeni
(L)
F Forbici
(F)
M Fusto
(M)
R Gagliardini
(R)
S Gebremeskel
(S)
F Gili
(F)
E Girardi
(E)
E Grilli
(E)
S Grisetti
(S)
I Mastrorosa
(I)
V Mazzotta
(V)
A Mondi
(A)
N Orchi
(N)
S Ottou
(S)
C Pinnetti
(C)
S Pittalis
(S)
D Pizzi
(D)
M Plazzi
(M)
A Vergori
(A)
A R Buonomini
(AR)
M Giuliani
(M)
A Latini
(A)
A Pacifici
(A)
C F Perno
(CF)
V Belvisi
(V)
C Del Borgo
(C)
A Carraro
(A)
M Lichtner
(M)
R Marocco
(R)
V Borghi
(V)
C Mussini
(C)
W Gennari
(W)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.